BRAF V600E co-occurs with a similar set of alterations in pediatric and adult tumors, and both patient groups can benefit from BRAF-targeted therapy ( In non-CNS solid cancers, BRAF V600E is frequently detected in malignant melanoma, hairy cell leukemia, colorectal carcinoma, and papillary thyroid carcinoma, as well as ovarian and lung tumors ( V600 mutation ( V600E -mutated melanoma were more likely to have CNS involvement than those with BRAF wild-type melanoma ( V600E expression cooperates with Pten tumor suppressor loss to generate metastatic melanoma without CNS involvement ( V600E in Cdkn2a Null mice generates melanomas without metastasis, but AKT1 activation promotes development of CNS metastases in this model ( In conclusion, BRAF V600E expression is a driver mutation of CNS tumors that occur in various neuroanatomic locations and exhibit a wide range of age at presentation
21 Possible role of the GPX4 gene in the development of CS A possible role of glutathione peroxidase-4 in the development of CS has been summarized in Figure 1
This combination strategy holds potential promise for reducing cisplatin dosage and associated toxicity, which provides insights into cannabinoids role as adjuvant agents in cancer treatment
Ressmeyer AR, Mayo JC, Zelosko V, et al
10.48162/rev.39.005 La Rev de la Facul de Cienc Agrarias
Koeglsperger et al., 2023)
